NCT05871021

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

A Phase IIa, Open-label, Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type, MGMT Unmethylated Glioblastoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 146 (estimated)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
RADIATION	Dose escalation of radiation dose beyond the therapeutic standard	Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab

Timeline

• Start date: 2024-04-10
• Primary completion: 2028-04-10
• Completion: 2028-07-10
• First posted: 2023-05-23
• Last updated: 2026-01-09

Locations

1 site across 1 country: Germany